Dataset Information
Homologous recombination deficiency in newly diagnosed advanced ovarian cancer across nine Middle East countries: prevalence, real-world testing pathways, and treatment implications.
Ontology highlight
ABSTRACT:
SUBMITTER: Shash E
PROVIDER: S-EPMC12930601 | biostudies-literature | 2026 Feb
REPOSITORIES: biostudies-literature
Publications
Homologous recombination deficiency in newly diagnosed advanced ovarian cancer across nine Middle East countries: prevalence, real-world testing pathways, and treatment implications.
BMC cancer 20260204 1
BACKGROUND: With current evidence of homologous recombination deficiency (HRD) emerging as a predictive and prognostic biomarker in high-grade serous/endometrioid ovarian cancers (HGSOC/HGEOC), the HALO study (NCT04991051) evaluated the prevalence of the HRD in patients with HGSOC/HGEOC, primary peritoneal cancer (PPC), and fallopian tube cancer (FTC) across Asia, Middle East and Africa (MEA), and Russia. METHODOLOGY: The MEA subset of this cross-sectional, non-interventional study enrolled pati ...[more]